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Changes in BRCA1 gene in patients with familial breast cancer
in the Warsaw region of Poland
Zygmunt Paszko, El˝bieta Skasko, Alicja WiÊniewska, Bo˝ena Konopka, Anna Kluska,
Agnieszka Jagielska, Ewa Wieczorek, Aneta Janiec-Jankowska, Anna Niwiƒska, 
Tadeusz Pieƒkowski,  S∏awomir Mazur.
52 patient-probands with a family history of breast cancer and other tumours were selected from among 500 breast cancer
patients treated at the Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology. We studied DNA
isolated from peripheral blood. The PCR-SSCP procedure was used for seeking mutations in all protein coding exons of the
BRCA1 gene. Fragments suspected of mutation presence were subjected to sequencing. In 36 probands of the  BRCA1 gene
11 types of changes were found in exons and 5 types in introns. In 19 (36.5%) probands no changes were detected within the
BRCA1 gene. Among exon changes 3 were ones generally  regarded as pathogenic mutations: 5382insC (3 families; 6 cases),
T300G (2 probands), 3819delGTAAA (1 proband). Among intron changes we suspect the IVS6 +28 (C→A) change to be
pathogenic, since it is present in intron area participating in exons splicing. It was found in three sisters (two had breast cancer,
one was healthy). The remaining 8 changes were disclosed in exons 11, 13 and 16 (A1186G, C2201T, T2430C, C2731T,
A3232G, A3668G, T4427C, A4956G) and regarded as polymorphisms. One of them, A1186G, was, as a heterozygotic
change, more frequent in breast cancer cases (18.8 %) than in healthy women (4%). We observed frequent presence of several
types of polymorhisms (3-6) in BRCA1 gene exons. Two heterozygotic changes (T300G and A1186G) in the blood DNA of
two unrelated patients lost  their heterozygosity in tumour DNA.
Zmiany w genie BRCA1 u chorych na rodzinnego raka sutka,
leczonych w Centrum Onkologii w Warszawie
SpoÊród przesz∏o 500 kobiet chorych na raka sutka, leczonych w Centrum Onkologii w Warszawie, wyselekcjonowano 52
probantki, które by∏y obarczone rodzinnym wyst´powaniem  kilku raków sutka i innych nowotworów. Materia∏em badawczym
by∏o DNA, izolowane z leukocytów krwi obwodowej. Procedurà PCR-SSCP pos∏ugiwaliÊmy si´ w celu poszukiwania mutacji
we wszystkich kodujàcych bia∏ko eksonach genu BRCA1. Fragmenty podejrzane o obecnoÊç mutacji poddawano
sekwencjonowaniu. U 36 probantek w genie BRCA1 wykryto 11 rodzajów zmian w eksonach i 5 rodzajów zmian w intronach.
U 19 (36,5%) probantek nie wykryto w genie BRCA1 ˝adnych zmian. WÊród zmian eksonowych trzy z nich  powszechnie
uznawane sà za mutacje patogenne: 5382insC (3 rodziny; 6 przypadków), T300G (2 probantki), 3819del5 (1 probantka).
SpoÊród zmian intronowych zmiana IVS6 +28 (C→A) podejrzewana jest przez nas o patogenne w∏aÊciwoÊci, gdy˝
umiejscowiona jest w obszarze intronu, który bierze udzia∏ w sk∏adaniu eksonów. Wyst´powa∏a ona u trzech sióstr (dwie chore
i jedna zdrowa). Pozosta∏ych 8 zmian, wykrytych w eksonach 11, 13 i 16 ( A1186G, C2201T, T2430C, C2731T, A3232G,
A3668G, T4427C, A4956G), to polimorfizmy. Jedna z nich - A1186G  wyst´powa∏a jako zmiana heterozygotyczna cz´Êciej
u chorych na raka sutka (18,8% ), ni˝ u kobiet zdrowych (4%). WÊród badanych chorych zaobserwowaliÊmy w eksonach genu
BRCA1 cz´ste nagromadzanie si´ u tej samej chorej kilku (3-6) polimorfizmów. Dwie heterozygotyczne zmiany (T300G i
A1186G), znalezione w DNA z krwi dwóch nie spokrewnionych chorych, utraci∏o swà heterozygotycznoÊç w DNA izolowanym
z guza. 
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Introduction
Since the time of BRCA1 and BRCA2 gene cloning, le-
sions of which can predispose to breast cancer develop-
ment in humans [1-4], new studies of these genes have
sprung up throughout the world. Until now over 400 va-
rious changes were found in the sequences of each gene,
such as missense mutations, nonsense mutation, dele-
tions, insertions etc. [5-7]. Some of them are evidently
pathogenic, while others are just polymorphic changes
of low importance for clinical medicine. The initial analy-
ses of the role of BRCA1 gene lesions in the develop-
ment of familial breast cancer had suggested that this ro-
le varies in a broad range from 9% to 79% [5]. Later the-
se values were recognised as overestimated, since in
certain population groups ethnic and social-cultural fac-
tors have lead to an accumulation of genetic traits de-
termining predispositions to hereditary breast cancer.
Recently it has been estimated that the role of the BRCA1
gene in the aetiology and pathogenesis of familial bre-
ast cancer can be estimated at between 11% and 17%
[6].
The first Polish study on the role of the BRCA1 and
BRCA2 genes in hereditary breast cancer was carried out
in the Poznaƒ region [8]. In the following years similar
studies were held in the Warsaw region [9, 10], in West
Pomerania [11] and in Silesia [12]. These studies concen-
trate on gathering data concerning the frequency and qu-
ality of changes in the BRCA1 and BRCA2 genes in pa-
tients with familial breast cancer.
The subject of this paper is to present the results of our
studies on BRCA1 gene changes in 52 women with fami-
lial breast cancer, inhabitants of the Warsaw region. We
are also conducting a BRCA2 gene study in this same
group of patients and intend to publish it separately. Fin-
ding the most frequent pathogenic mutations of BRCA1
and BRCA2 genes for the Polish population will allow to
define basic founder mutations predisposing to breast
cancer development and will contribute towards more
efficient genetic counselling of patients.
Material and methods
Pa t i e n t s
From over 500 women treated during a period of 3 years at the
Department of Breast Cancer and Reconstructive Surgery of
The Maria Sklodowska-Curie Memorial Cancer Centre in War-
saw 52 patients (age: 24-72 years; median 48 years) were selected
due to a history of breast cancer and other tumours among fami-
ly members. Over 65% of these women were inhabitants of War-
saw.
In the families of the selected patient-probands the number
of breast cancer cases veried between 1 and 6, within the first or
second degree of kinships. In two families the number of breast
cancer cases was 5 and 6; in 6 families – 4 cases in each family, in
14 families – 3 cases, in 19 families – 2 cases (Table I). Among
the studied patients two were mother-daughter relatives (Table
I, nos. 5 and 6), six were sister pairs (Table I patients no 1 and
1A, no 23 and 24, no 40 and 44, no 52 and 56, no 63 and 65, no
78 and 80). Seven patients had no family history of breast cancer.
They were included into the study for the following reasons:
very young age (<40 years), family history of ovarian or prosta-
tic cancer, presence of bilateral breast cancer, or several neopla-
sms, in the same patient (e. g. patients no 22 and 26 had breast,
ovarian and endometrial cancers). In the families of the selected
patients the number of cancer cases other than breast cancer va-
ried between 1 and 7. These included cancer of the ovaries, the
prostate, the endometrium, the kidney, the pancreas, the gall-
bladder, the lungs, brain tumours, myeloma and lymphoma.
M e t h o d s
We studied DNA isolated from peripheral blood obtained from
52 patients with breast cancer and from 25 healthy persons who
had no near relatives with malignant neoplasms. In several cases
tumour tissue was used also for examination. Blood and tumour
tissue was kept at -70°C until DNA isolation with the phenol-
-chloroform method using proteinase K. The isolation proce-
dure was performed according to Sambrook et al. [13].
The PCR-SSCP procedure was used for seeking mutations
in all protein coding exons of the BRCA1 gene. Due to its exces-
sive size exon 11 was amplified in 23 fragments. The primers
for the PCR reaction were as proposed by Friedman et al. [14].
Polymerase chain reaction (PCR) of genomic DNA was
carried out in 25 µl volume containing 200 ng (5 µl) of genomic
DNA, 2.5 µl of PCR buffer (20mM tris/HCl pH 8.4, 50 mM
KCl (Perkin Elmer – PE), 200 µM (1 µl) of each deoxynucleoti-
de (dATP, dTTP, dCTP, dGTP), 0.5 µM (0.6 µl) of forward and
reverse primers, 2.5 mM (2.5 µl) MgCl2, and 1.5 U (0.3 µl).
Ampli Taq Gold polymerase (PE), and ddH20 up to 25 µl of to-
tal volume. Amplification was performed in a Perkin Elmer
9600 DNA Thermal cycler.
PCR amplification conditions were as follows: denaturing
at 95°C for 10 min, (30 cycles of denaturing at 94°C for 20 s., an-
nealing for different primer pairs at between 50°C and 62°C for
20 s. and extension at 72°C for 20 s.), extension at 72°C for 7 min.
SSCP analysis
Amplified samples diluted with formamide (1:1) were denatured
at 95°C for 6 min. Next they were cooled rapidly to 4°C and
held for at least 2-3 min. For each sample 5 µl was loaded onto
the non-denaturing 12.5% polyacrylamide gel and run at 600
V voltage, 10-15°C temperature, 2 h 30 min. time. The electro-
phoregrams were stained with Plus One DNA Silver Staining Kit
(Pharmacia). The results of electrophoretic separation of DNA
fragments from the patients were compared with analogous
samples from healthy persons. Fragments suspected of muta-
tion presence were subjected to sequencing. However, some
DNA samples, especially those from patients with high num-
ber of breast cancer cases in their families, were sequenced di-
rectly without prior SSCP analysis. Total sequencing material
was 70%.
S e q u e n c i n g
The amplified DNA samples were purified with Centricon-100
columns (PE) and were then subjected to sequencing PCR.
Then 10 µl of volume containing 30 – 90 ng purified DNA, for-
ward or reverse primer 1.6 pmol, 4 µl Big Dye Terminator Ready
Reaction Mix (PE) were used for sequencing reaction. Cycling
conditions of sequencing reaction were as follows: 95°C- 2min.,
(96°C-10 sec, temperature of primer annealing 50°C – 60°C – 5
sec., 60°C – 4 min. -25 cycles). Sequencing primers were the sa-
me as those used to amplify the template. The product of the se-
quencing reaction was purified in spin columns (Centri Sep PE).
Sequence was run on 5% denaturing polyacrylamide gel (Long
Range gel solution) at 2,4 kV voltage for 7 hours in ABI Prism
377 Perkin Elmer apparatus.
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Results
In the group of 52 patients tested by the PCR-SSCP pro-
cedure or direct sequencing in 33 patients 11 types of
changes were found in BRCA1 gene exons. These changes
present with a frequency from 1.9% to 37.5% of cases
were found in exons 5 (T300G), 11 (A1186G, C2201T,
T2430C, C2731T, A3232G, A3668G, 3819del5), 13
(T4427C), 16 (A4956G) and 20 (5382insC). In the rema-
ining 19 (36.5%) patients no changes were detected. The-
se results are presented in Table I and Figure 1. In two
unrelated patients (nos. 3 and 18) the changes in positions
T300G and A1186G were found in blood DNA as hetero-
zygotic, but in their tumour DNA these changes lost the-
ir heterozygosity.
The starters used for sequencing on both sides of
the exons overlapped intron fragments. This allowed for
the detection of changes not only in exons, but also in
intron fragments adjacent to initial or final parts of exons.
We found 5 different intron changes which had heterozy-
gotic or homozygotic character. These changes are pre-
sented on the Figure 1.
The most frequent intron changes were: IVS17
–67 (A→G), IVS18 +66 (G→A), and IVS8 –34 (C→T)
which was found in 12, 10 and 8 patients respectively.
The most infrequent were changes in IVS2 +80 (A→G)
and IVS6 +28 (C→A) detected in 2 and 3 patients re-
spectively.
The IVS6 +28 change (C→A) is located in the area
which participates in exons splicing. It was detected
in three sisters, two of whom had breast cancer
(Table I no 23 and 24) and the third (not shown in Ta-
ble I) was healthy. In all three sisters this change was
present in both alleles in blood DNA. Although in each si-
ster the whole protein coding part of BRCA1 gene was se-
quenced, no changes other than IVS6 +28 were found in
the gene.
Discussion
Among the DNA obtained from 52 studied women only 3
theoretically pathogenic mutations types were found. One
of them was detected in nucleotide position T300G: ami-
no acid effect – Cys61Gly, predictive protein effect – loss
of zinc motive. We have disclosed this mutation only in 2
out of 52 patients, what is more – unrelated. An analogo-
us defect was detected by Friedman et al. [14] and Górski
et al. [11]. It has also been recorded in the Breast Cancer
Information Core (BIC) [7] 44 times as missense muta-
tion.
The second mutation found in our material was a de-
letion of 5 nucleotides in exon 11 in position 3819delGTA-
AA, the consequence of which is the stop signal in codon
1242. It was found only in one out of 52 patients. The
same mutation was found twice in our country, by Górski
et al. [11]. In the BIC it has been recorded 10 times.
The third mutation was found in exon 20. It was
5382insC in codon 1755 (its consequence being a stop in
codon 1829). We found it in 3 families (table I: mother-
-daughter Nos. 5 and 6, two sister pairs nos. 63 and 65,
Figure 1. Germline changes found in BRCA1 gene in patients with familial breast cancer in Warsaw District.
P – polymorphism; MS – missense; F – frameshift; del – deletion; ins – insertion; * – heterozygosity, ** – homozygosity, n – number of cases.
In the scheme of BRCA1 gene the relation between dimension of exons is disregarded.
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and nos. 78 and 80). In Poland this mutation was found
earlier in Silesia, in the Poznaƒ region [12] and in West
Pomerania [11]. In the BIC it has been recorded 190 ti-
mes [15].
Among 8 further changes detected in exons of the
BRCA1 gene, six were present in exon 11, one in exon
13 and one in exon 16. Three of them had no consequen-
ces in the changes in amino acid pattern of proteins (exon
11 – C2201T – Ser694Ser, T2430C – Leu771Leu, and
exon 13 T4427C – Ser1436Ser). They were found also by
Friedman et al. [14] and they are recorded in the BIC.
One of the heterozygotic changes is of interest – the
A1186G with consequence – Gln356Arg, which was mo-
re frequent in patients with breast cancer (9/48 – 18.8%),
than in healthy women (1/25 cases – 4%). The change in
position A1186G has been recorded in the BIC only once
and defined as missense change without any biological
consequence known as yet.
In 2 unrelated patients (Table I no 3 and 18) 2 hete-
rozygotic changes – T300G and A1186G found in blood
DNA and in tumour DNA occurred lost of their heterozy-
gosity. The fact of above described coexistance of these
changes in two unrelated patients with breast cancer sug-
gest an interrelationship between these changes.
One of the most frequent changes (37.5%) in
our material was a change in the nucleotide C2731T
(Pro871Leu), which was also found in 46% of healthy
women. We could not find this change in the BIC re-
cords.
We found the change A3232G (Glu1038Gly) in only
one case; in the BIC it has been recorded 4 times. The
biological effect of this change remains unknown. The
next exon change – A4956G (Ser1613Gly) was found
3 times in our material, while in the BIC it is recorded twi-
ce as a polymorphism. The last exon change –
A3668G (Lys1183Arg) found only once in our material
has been recorded 26 times in the BIC as a polymor-
phism.
We have detected 5 types of intron changes in the
form of homozygotes or heterozygotes with a predomi-
nance of the former ones (Figure 1). Presently we cannot
express any opinion on the participation of respective in-
tron changes in the pathogenesis of breast cancer. Howe-
ver, it should be stressed that intron change (C→A) in po-
sition IVS6 +28 is located in the area participating in
exons splicing. This was the only change in the BRCA1 ge-
ne found in blood DNA of the previously mentioned
three sisters, and therefore its possible biological consequ-
ence should be studied.
Reviewing the studied material one can see that pa-
thogenic mutations occurred in patients with a family hi-
story of 2 to 5 cases of breast cancer and 1 to 5 other
neoplasms. However, 19 patients with no pathogenic
changes detected had families with 1 to 5 breast cancer
cases in addition to 1 to 7 other tumours. It would be in-
teresting to know what are the reasons for not detecting
pathogenic mutations in such a considerable number of
our patients (36.5%). One of the reasons may be overlo-
oking pathological mutations due to methodological gro-
unds. PCR- SSCP technique does not detect all changes.
As it has been mentioned above, only 70% of our material
was sequenced.
Polymorphisms A1186G and C2731T were more fre-
quent in patients with higher numbers of breast cancer ca-
ses in the family. Are the supposedly polymorphisms real-
ly so neutral with respect to breast cancer pathogenesis or
whether their frequent cumulation in one person is an
evidence of an "unrest" occurring in genome DNA?
Among our patients we have observed cases with 3 to 6
various polymorphisms. Friedman et al. [3] have reported
that the presence of disequilibrium between polymorphi-
sms has led them to finding 10 families with pathogenic
mutations.
Assuming that there may occur a typical 185delAG
Jewish mutation in the Polish population, we have exami-
ned all our patients DNA by means of sequencing se-
cond exon. The mutation, however, has not been found.
185 del AG mutation is a change commonly found thro-
ughout the world, and it has also been detected in several
centers in Poland [12].
5382insC change, commonly known throughout the
world as founder mutation, is observed among Ashkena-
zi Jews [16] and in Eastern Europe [17]. It is the most
frequently observed change in our material (6/9 pathoge-
nic mutations – 66.7% – Table I).
As in our study we have found mutations generally
regarded as pathogenic in 9 cases we have calculated that
in the Warsaw region the BRCA1 gene changes connected
with breast cancer occur in 17.3% cases. This value lies
within the range estimated for the world population i. e.
11-17% [6].
Of the three types of pathogenic mutations found
in our material the most frequent was 5382insC (3 fami-
lies), less frequent was the T300G mutation (2 families)
and the least frequent was 3819del5 mutation (in one fa-
mily). Intron change IVS6 +28 (C→A) was present in
one family. All these changes, except IVS6 +28 (C→A)
intron mutation, were found also in the West Pomera-
nian and Silesian regions [12]. As for the changes descri-
bed by Sobczak et al. [8] in the Poznaƒ region, i.e. exon 11
– codon/nucleotide 1345/4153, exon 22 – 1782/5465, exon
7 – 105/433 and double insertion of GTATTCCACTCC
fragment in intron 20 we did not come across them in
the Warsaw region subpopulation.
So far research on the BRCA2 gene mutation con-
ducted on the same human material has not revealed any
serious mutations in the BRCA2 gene, apart from some
nonpathogenic polymorphisms. Considering the occur-
rence of tumours linked to mismatch repair genes
(hMLH1 and hMSH2) or TP53 gene in our patients' fami-
lies, research is also being carried out in this direction.
Zygmunt Paszko MD, Ph.D.
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